Lyell Immunopharma (LYEL) Current Deferred Revenue (2020 - 2022)

Lyell Immunopharma has reported Current Deferred Revenue for 3 years, with the latest figure at $11.2 million in Q3 2022.

• Quarterly Current Deferred Revenue rose 100.52% year-over-year to $11.2 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $11.2 million (up 100.52% YoY) and the FY2021 annual result came in at $5.0 million, down 88.92% from the prior year.
• Current Deferred Revenue declined to $11.2 million in Q3 2022 per LYEL's latest filing, from $15.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $45.0 million in Q4 2020 and troughed at $5.0 million in Q4 2021.
• A 3-year average of $13.8 million and a median of $8.2 million in 2021 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue tumbled 88.92% in 2021, then surged 100.52% in 2022.
• Over 3 years, Current Deferred Revenue stood at $45.0 million in 2020, then sank by 88.92% to $5.0 million in 2021, then surged by 124.36% to $11.2 million in 2022.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $11.2 million, $15.4 million, and $6.2 million for Q3 2022, Q2 2022, and Q1 2022 respectively.